<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365688">
  <stage>Registered</stage>
  <submitdate>22/01/2014</submitdate>
  <approvaldate>28/01/2014</approvaldate>
  <actrnumber>ACTRN12614000101684</actrnumber>
  <trial_identification>
    <studytitle>Melatonin vs. placebo for the symptoms of delirium in elderly medical inpatients</studytitle>
    <scientifictitle>A double blinded, randomised, placebo controlled pilot trial of moderate dose melatonin for the abatement and
treatment of delirium in elderly general medical inpatients.</scientifictitle>
    <utrn>U1111-1152-4837</utrn>
    <trialacronym>MFDAT</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>delirium</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Melatonin 5mg oral capsule nightly for 5 days administered directly by hospital nursing staff.</interventions>
    <comparator>Placebo - identical capsule but for active ingredient.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptoms of delirium - Memorial Delirium Assessment Scale.</outcome>
      <timepoint>Average during treatment assessed daily over the 5 day treatment period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms of delirium - Memorial Delirium Assessment Scale.</outcome>
      <timepoint>Following treatment cessation, on days 6 and 7 of the trial (medication on days 1-5)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of delirium (regardless of cause)
Inpatient under general medicine of the The Royal Melbourne Hospital</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusively hypoactive delirium, recent stroke (&lt;14 days), sensory impairment or dysphasia or language such that not evaluable, undergoing surgery, prognosis &lt;7days, severe hepatic or renal failure, allergy or intolerance to melatonin or excipients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Permuted block opaque envelopes with random allocation by trial pharmacist</concealment>
    <sequence>Permuted block</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>n/a</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Descriptive</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/03/2014</anticipatedstartdate>
    <actualstartdate>19/05/2014</actualstartdate>
    <anticipatedenddate>19/01/2016</anticipatedenddate>
    <actualenddate>27/07/2016</actualenddate>
    <samplesize>36</samplesize>
    <actualsamplesize>29</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>3/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <postcode>3050 - Royal Melbourne Hospital</postcode>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Royal Melbourne Hospital</primarysponsorname>
    <primarysponsoraddress>Grattan street
THE ROYAL MELBOURNE HOSPITAL
VIC 3051</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Royal Melbourne Hospital</fundingname>
      <fundingaddress>Grattan street
THE ROYAL MELBOURNE HOSPITAL
VIC 3051</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a pilot trial testing the feasibility and participants required to test the hypothesis that melatonin 5mg capsule every night will decrease the symptoms of delirium in elderly medical inpatients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>n/a</publicnotes>
    <ethicscommitee>
      <ethicname>Melbourne Health HREC</ethicname>
      <ethicaddress>Grattan street
THE ROYAL MELBOURNE HOSPITAL
VIC 3051</ethicaddress>
      <ethicapprovaldate>8/05/2014</ethicapprovaldate>
      <hrec>2014.037</hrec>
      <ethicsubmitdate>29/01/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Peter Lange</name>
      <address>c/o APU, Ground Floor,
The Royal Melbourne Hospital,
Grattan st,
THE ROYAL MELBOURNE HOSPITAL
VIC 3050</address>
      <phone>+61393424835</phone>
      <fax />
      <email>peter.lange@msn.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Peter Lange</name>
      <address>c/o APU, Ground Floor,
The Royal Melbourne Hospital,
Grattan st,
THE ROYAL MELBOURNE HOSPITAL
VIC 3050</address>
      <phone>+61393424835</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Peter Lange</name>
      <address>c/o APU, Ground Floor,
The Royal Melbourne Hospital,
Grattan st,
THE ROYAL MELBOURNE HOSPITAL
VIC 3050</address>
      <phone>+61393424835</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>